AVAX Technologies Inc (fka AVXT)

[newtechinvestor]

Recent article mentions Avax Tech.


Vaccines are big business. According to CBDM.T®, the vaccine market is a huge and growing market valued at €16 billion in 2008 with an annual growth of about 15 to 18%. USA sales account for 45% of total vaccine sales. The vaccine market could account for more than €25 billion by 2012. If we look at the top 5 pharmaceutical companies, vaccine sales represent between 8 to 9% of their total sales. The top 20 vaccines brands account for 80% of total vaccine sales. Large companies have recently attempted to acquire market share. In 2005, Novartis bought Chiron's remaining 58% for $5.1 billion (now making 100%). "Vaccines continue to emerge as significant value drivers for major pharma. A promising alternative to conventional vaccines, DNA vaccines, is under late clinical phase development" comments Philippe Tramoy, managing partner.

Key players: Sanofi-Aventis, Sanofi-Pasteur, GSK, Wyeth, Merck, Norvartis, Chiron, Avax Technologies, CSL Biotherapies, Omrix biopharmaceuticals, Epimmune, Oxxon Therapeutics, Vical, Fit Biotech, Genencor, Innogenetics.


http://snk.aes-int.cn/foot/446699